Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer

Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer

Abstract Background Trastuzumab (Herceptin® [H]) is the standard of care for HER2-positive locally advanced/metastatic breast cancer and gastric/gastroesophageal junction (GEJ) cancer. However, there is a paucity of data available on long-term H treatment of patients. The Rollover Protocol (ROP) Stu...

Full description

Bibliographic Details
Main Authors: Volkmar Müller, Michael Clemens, Jacek Jassem, Nedal Al-Sakaff, Petra Auclair, Eveline Nüesch, Debbie Holloway, Mona Shing, Yung-Jue Bang
Format: Article
Language:English
Published: BMC 2018-03-01
Series:BMC Cancer
Subjects:
Herceptin
Trastuzumab
Breast cancer
Gastric cancer
HER2-positive
Online Access:http://link.springer.com/article/10.1186/s12885-018-4183-2

Internet

http://link.springer.com/article/10.1186/s12885-018-4183-2

Similar Items